1095 related items for PubMed ID: 16971719
1. Oral fingolimod (FTY720) for relapsing multiple sclerosis.
Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW, FTY720 D2201 Study Group.
N Engl J Med; 2006 Sep 14; 355(11):1124-40. PubMed ID: 16971719
[Abstract] [Full Text] [Related]
2. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
[Abstract] [Full Text] [Related]
3. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group.
N Engl J Med; 2010 Feb 04; 362(5):402-15. PubMed ID: 20089954
[Abstract] [Full Text] [Related]
4. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA, TRANSFORMS Study Group.
Lancet Neurol; 2011 Jun 04; 10(6):520-9. PubMed ID: 21571593
[Abstract] [Full Text] [Related]
5. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD.
Lancet Neurol; 2014 Jun 04; 13(6):545-56. PubMed ID: 24685276
[Abstract] [Full Text] [Related]
6. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.
Comi G, O'Connor P, Montalban X, Antel J, Radue EW, Karlsson G, Pohlmann H, Aradhye S, Kappos L, FTY720D2201 Study Group.
Mult Scler; 2010 Feb 04; 16(2):197-207. PubMed ID: 20028707
[Abstract] [Full Text] [Related]
7. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L, FREEDOMS study group.
Lancet Neurol; 2012 May 04; 11(5):420-8. PubMed ID: 22494956
[Abstract] [Full Text] [Related]
8. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
Radue EW, O'Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, Zhang-Auberson L, Francis G, Burtin P, Kappos L, FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group.
Arch Neurol; 2012 Oct 04; 69(10):1259-69. PubMed ID: 22751847
[Abstract] [Full Text] [Related]
9. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.
Kappos L, O'Connor P, Radue EW, Polman C, Hohlfeld R, Selmaj K, Ritter S, Schlosshauer R, von Rosenstiel P, Zhang-Auberson L, Francis G.
Neurology; 2015 Apr 14; 84(15):1582-91. PubMed ID: 25795646
[Abstract] [Full Text] [Related]
10. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis.
Saida T, Kikuchi S, Itoyama Y, Hao Q, Kurosawa T, Nagato K, Tang D, Zhang-Auberson L, Kira J.
Mult Scler; 2012 Sep 14; 18(9):1269-77. PubMed ID: 22354739
[Abstract] [Full Text] [Related]
11. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension.
Kira J, Itoyama Y, Kikuchi S, Hao Q, Kurosawa T, Nagato K, Tsumiyama I, von Rosenstiel P, Zhang-Auberson L, Saida T.
BMC Neurol; 2014 Jan 29; 14():21. PubMed ID: 24475777
[Abstract] [Full Text] [Related]
12.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
13. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis.
Barkhof F, de Jong R, Sfikas N, de Vera A, Francis G, Cohen J, TRANSFORMS study group.
Mult Scler; 2014 Nov 29; 20(13):1704-13. PubMed ID: 24812043
[Abstract] [Full Text] [Related]
14. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT, DEFINE Study Investigators.
N Engl J Med; 2012 Sep 20; 367(12):1098-107. PubMed ID: 22992073
[Abstract] [Full Text] [Related]
15. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
Singer B, Ross AP, Tobias K.
Int J Clin Pract; 2011 Aug 20; 65(8):887-95. PubMed ID: 21679286
[Abstract] [Full Text] [Related]
16. Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the national multiple sclerosis registry in Kuwait.
Al-Hashel J, Ahmed SF, Behbehani R, Alroughani R.
CNS Drugs; 2014 Sep 20; 28(9):817-24. PubMed ID: 25011422
[Abstract] [Full Text] [Related]
17. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.
Ward MD, Jones DE, Goldman MD.
Expert Opin Drug Saf; 2014 Jul 20; 13(7):989-98. PubMed ID: 24935480
[Abstract] [Full Text] [Related]
18. Use of fingolimod in patients with relapsing remitting multiple sclerosis in Kuwait.
Alroughani R, Ahmed SF, Behbehani R, Al-Hashel J.
Clin Neurol Neurosurg; 2014 Apr 20; 119():17-20. PubMed ID: 24635919
[Abstract] [Full Text] [Related]
19. Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.
Vasiliou S.
Drugs Today (Barc); 2010 May 20; 46(5):315-25. PubMed ID: 20517533
[Abstract] [Full Text] [Related]
20. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
Scott LJ.
CNS Drugs; 2011 Aug 20; 25(8):673-98. PubMed ID: 21790210
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
